Table 3.

Model inputs: effectiveness measures

	Overall		Rash subgroup
	Erlotinib (N=334)	Placebo (N=313)	Erlotinib (N=178)	Placebo (N=278)
Mean OS (months)	7.08 (0.48)	6.41 (0.44)	9.08 (0.65)	6.91 (0.43)
Mean PFS (months)	4.95 (0.36)	3.80 (0.29)	6.22 (0.51)	4.19 (0.32)
Mean PPS (months)	2.13 (0.250)	2.61 (0.236)	2.86 (0.41)	2.72 (0.27)
HR (OS)	0.92		0.76
(95% CI; p value)	(0.79 to 1.08; p value=0.32)		(0.63 to 0.92; p value=0.005)
HR (PFS)	0.81		0.66
(95% CI; p value)	(0.70 to 0.95; p value=0.0102)		(0.54 to 0.80; p value<0.0001)
Utilities
Preprogression EQ-5D (mean, SE)	0.6482 (0.009)	0.6438 (0.011)	0.6407 (0.017)	0.6193 (0.015)
Postprogression EQ-5D (mean, SE)	0.5517 (0.016)	0.5760 (0.014)	0.5548 (0.0255)	0.5756 (0.020)
QALY (years)*	0.365 (0.0272)	0.3303 (0.0245)	0.487 (0.0432)	0.3472 (0.0260)†
Incremental QALY (mean SE)‡		0.035 (0.0163)		0.139 (0.0113)

*This is computed as (preprogression utility)×PFS+(postprogression utility)×PPS.

†Statistically different between erlotinib and placebo (p value: 0.0070).

‡Erlotinib versus placebo.

PFS, progression-free survival; PPS, postprogression survival; OS, overall survival.